Every UK-facing online medicine sale is subject to MHRA distance-selling regulations. The rules are clear, the enforcement is real, and the failure modes are expensive. This piece walks through what 'distance selling' actually covers, the registry that replaced the EU common logo post-Brexit, the constraints on POM/P/GSL marketing, and what MHRA enforcement looks like when it happens.
What 'distance selling' covers in the MHRA framework
Distance selling covers any sale or supply of medicines to UK patients without face-to-face interaction. That includes online pharmacies, telephone orders, and the dispensing layer of any telehealth brand. MHRA registers retailers of medicines and maintains a UK register of online retailers, which is the authoritative list of permitted operators.
The EU common logo and the UK registry that replaced it post-Brexit
Before 2021, UK online medicine retailers displayed the EU common logo on their websites. Post-Brexit, this was replaced by entry in the MHRA's UK register of online retailers of medicines. Patients can verify a retailer's status by checking the register directly. Operators must register and maintain accurate details.
Prescription verification requirements
All POM (Prescription-Only Medicine) dispenses require a valid UK prescription verified by a registered prescriber. The prescription must be from a clinician licensed to prescribe in the UK; foreign prescriptions are not valid. The pharmacy must retain the prescription record for audit purposes.
Marketing constraints on POM, P, and GSL medicines
POM (Prescription-Only Medicines) cannot be advertised directly to the UK public under MHRA rules — including indirect marketing that mentions the medicine by name or product class. P (Pharmacy) medicines must be sold under supervision of a registered pharmacist. GSL (General Sales List) medicines are unrestricted but still subject to advertising rules. The boundary is where most brand-level breaches occur.
What MHRA enforcement looks like — recalls, audits, prosecutions
MHRA can issue enforcement notices, conduct unannounced inspections, mandate product recalls, and prosecute operators. Enforcement actions are typically reported publicly. The reputational cost usually exceeds the financial penalty. MHRA's relationship to operators is broadly cooperative until breaches occur, then assertively prosecutorial.
Reporting suspected counterfeit or sub-standard products
Operators have a legal and ethical duty to report suspected counterfeit or sub-standard medicines to MHRA through the Yellow Card scheme and dedicated reporting routes. This is not optional and is closely watched.
POM marketing is the single most common ASA-and-MHRA breach in UK telehealth. Prescriber-led copy is the compliant workaround. Direct product naming in patient-facing ads is not.
MHRA enforcement is broadly cooperative until breaches occur, then assertively prosecutorial.
MHRA compliance is structural. Get it right at signing — through your dispensing partner, your advertising templates, and your prescription verification flow — and most of the day-to-day work disappears. Get it wrong and the cost compounds.
